neomycin brands

29 registered brands containing neomycin in Malawi.

neomycin

PubChem CID 8378

Molecular formula: C23H46N6O13

Framycetin binds to specific 30S-subunit proteins and 16S rRNA, four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. Like other aminoglycoside antibiotic drugs, neomycin inhibits bacterial ribosomes by binding to the 30S ribosomal subunit of susceptible bacteria and disrupting the translational machinery of bacterial protein synthesis. Bacterial translation is normally initiated by the mRNA binding to the 30S ribosomal subunit and subsequent binding with 50S subunit for elongation. Aminoglycosides are usually bactericidal in action. Although the exact mechanism of action has not been fully elucidated, the drugs appear to inhibit protein synthesis in susceptible bacteria by irreversibly binding to 30S ribosomal subunits. /Aminoglycosides/ A class of angiogenesis inhibitor has emerged from our mechanistic study of the action of angiogenin, a potent angiogenic factor. Neomycin, an aminoglycoside antibiotic, inhibits nuclear translocation of human angiogenin in human endothelial cells, an essential step for angiogenin-induced angiogenesis. The phospholipase C-inhibiting activity of neomycin appears to be involved, because U-73122, another phospholipase C inhibitor, has a similar effect. In contrast, genistein, oxophenylarsine, and staurosporine, inhibitors of tyrosine kinase, phosphotyrosine phosphatase, and protein kinase C, respectively, do not inhibit nuclear translocation of angiogenin. Neomycin inhibits angiogenin-induced proliferation of human endothelial cells in a dose-dependent manner. At 50 microM, neomycin abolishes angiogenin-induced proliferation but does not affect the basal level of proliferation and cell viability. Other aminoglycoside antibiotics, including gentamicin, streptomycin, kanamycin, amikacin, and paromomycin, have no effect on angiogenin-induced cell proliferation. Most importantly, neomycin completely inhibits angiogenin-induced angiogenesis in the chicken chorioallantoic membrane at a dose as low as 20 ng per egg. These results suggest that neomycin and its analogs are a class of agents that may be developed for anti-angiogenin therapy. ... Aminoglycosides are aminocyclitols that kill bacteria by inhibiting protein synthesis as they bind to the 16S rRNA and by disrupting the integrity of bacterial cell membrane. Aminoglycoside resistance mechanisms include: (a) the deactivation of aminoglycosides by N-acetylation, adenylylation or O-phosphorylation, (b) the reduction of the intracellular concentration of aminoglycosides by changes in outer membrane permeability, decreased inner membrane transport, active efflux, and drug trapping, (c) the alteration of the 30S ribosomal subunit target by mutation, and (d) methylation of the aminoglycoside binding site. ... /Aminoglycosides/

Source: PubChem (NCBI) ยท compound 8378

Product Manufacturer Status Country
BECLASONE-N COMBINATION PRODUCT CREAM
CREAM
- Registered Malawi
BECLEM COMBINATION PRODUCT OINTMENT
OINTMENT
- Registered Malawi
BETALEB N 0.1%W/W, 0.5%W/W CREAM
CREAM
- Registered Malawi
CICATRIN COMBINATION PRODUCT POWDER
POWDER
- Registered Malawi
CLEANBACT TRIPLE ACTION COMBINATION PRODUCT CREAM
CREAM
- Registered Malawi
DEMONA N EYE 0.5%/0.1%W/V SOLUTION
SOLUTION
- Registered Malawi
DERMA-PLUS 0.064%W/W , 0.5%W/W CREAM
CREAM
- Registered Malawi
DEXACORAL-N COMBINATION PRODUCT EYE/ EAR DROPS
EYE/ EAR DROPS
- Registered Malawi
DEXONA COMBINATION PRODUCT EYE/EAR DROPS
EYE/EAR DROPS
- Registered Malawi
FUNBACT-A COMBINATION PRODUCT CREAM
CREAM
- Registered Malawi
FUNBACT N 0.1/5MG/ML EYE/EAR DROPS
EYE/EAR DROPS
- Registered Malawi
GYNANFORT COMBINATION PRODUCT PESSARY
PESSARY
- Registered Malawi
GYNOMIX SOFT COMBINATION PRODUCT VIGINAL SUPPOSITORIES
VIGINAL SUPPOSITORIES
- Registered Malawi
IVYBETANEOCIN EYE/EAR 0.1%W/V & 0.35%W/V DROPS
DROPS
- Registered Malawi
IVYDEXNEOCIN EYE/EAR 0.1%/0.35%W/V DROPS
DROPS
- Registered Malawi
MECLODERM BN COMBINATION PRODUCT CREAM
CREAM
- Registered Malawi
N.C.O MIX WSP COMBINATION PRODUCT POWDER
POWDER
- Registered Malawi
NEOCIN COMBINATION PRODUCT OINTMENT
OINTMENT
- Registered Malawi
NEODEXONE COMBINATION PRODUCT EYE DROPS
EYE DROPS
- Registered Malawi
NEODEXONE COMBINATION PRODUCT EYE OINTMENT
EYE OINTMENT
- Registered Malawi
NEOMYCIN/BACITRACIN COMBINATION PRODUCT OINTMENT
OINTMENT
- Registered Malawi
NEOMYCIN DEXAMETHASONE COMBINATION PRODUCT SOLUTION
SOLUTION
- Registered Malawi
PANDERM COMBINATION PRODUCT OINTMENT
OINTMENT
- Registered Malawi
SULFABIOTIC COMBINATION PRODUCT DUSTING POWDER
DUSTING POWDER
- Registered Malawi
SULFABIOTIC COMBONATION PRODUCT DUSTING POWDER
DUSTING POWDER
- Registered Malawi
WW NEODEX 0.1% & 3.5% EYE DROPS
EYE DROPS
- Registered Malawi
XBETA-N 0.5%/0.1%W/V SOLUTION(EYE/EAR/NASAL DROPS)
SOLUTION(EYE/EAR/NASAL DROPS)
- Registered Malawi
XSONE-N 0.3%W/V EYE/EAR DROPS
EYE/EAR DROPS
- Registered Malawi
ZOLECON COMBINATION PRODUCT CREAM
CREAM
- Registered Malawi